Tel: 1-631-626-9181 (USA)    44-207-097-1828 (Europe)
  Email:

CBpromise   

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER

CAR-T/CAR-NK Cells Generation Service

T cells from a healthy patient′s blood are collected and are genetically modified to express an artificial receptor consisting of the variable fragment of an antibody specific for a cell surface molecule involved in T cell signaling. CAR-T cells are then propagated in cell culture until they reach several billions in number, and injected back into the patient′s blood stream. After infusion, CAR-T cells are designed to recognize tumor cells and kill them.

A typical CAR T cell therapy involves four basic steps:

  1. Collect the T cells from the patient’s own blood.
  2. T cells are genetically engineered to express CAR.
  3. These engineered CAR-T cells are then grown and differentiated in vitro.
  4. Inject CAR-T cells back into the patient′s blood stream.

CAR-TCAR-NK Cells Generation Service

Figure 1. Process of a typical CAR T cell therapy

Our scientists bring years of extensive experience in generation of stable cell lines. Creative Biogene provides services for generation of CAR-T/CAR-NK cells that can target different tumor antigens that are highly over-expressed in tumors based on Lentiviral vector. We provide you one stop service including constructing the lentivirus expression vector, CAR lentiviral packaging, CAR-T/CAR-NK cells generation and validation. Besides, our CAR-T/CAR-NK cells in stock can save your precious time and effort in your research.

Creative Biogene’s CAR-T/CAR-NK cells generation service has the following features:

  1. One-stop service: including constructing the lentivirus expression vector, CAR lentiviral packaging, CAR-T/CAR-NK cells generation and validation.
  2. Experienced: Creative Biogene has professional research team with experience of many years in the field of cell generation.
  3. Genetic stability: Our CAR-T/CAR-NK cells have been rigorously tested and validated (transduction efficiency, CAR expression, IFN-gamma ELISA, cell killing activity).
Associated malignancyTarget antigenCARs generation
FirstSecondThird
LeukemiaCD19
k-light chain
CD33
CD123
WT1
Pr3
LymphomaCD19
CD20
CD22
CD30
k-light chain
Breast and otherserb-B2
erb-B2,3,4
MUC1
LeY
Prostate cancererb-B2
PSCA
Colorectal cancerEGP-40
erb-B2
Lung malignancyHer2/neu
AdenocarcinomasTAG-72
Cervical carcinomaCD44v7/8
MelanomaGD3
MAGE-A1
Renal cell carcinomaCAIX
Epithelial derived tumorsLeY
Advanced osteosarcomaHer2/neu
RhabdomyosarcomaFetal acethylcholine receptor
Ewing’sGD2
sarcomaNKG2D
MUC1
survivin
CSPG4
MedulloblastomaHer2/neu
IL-13R-a2
NeuroblastomaGD2
L1 cell adhesion molecule
CD171
EGFRvIII
ROR1
Ovarian cancerα-Folate receptor
FBP
MUC1
GliomaHer2/neu
IL-13R-a2
Multiple malignanciesEGP-2
Various tumorsMesothelin
NKG2D ligands
Tumor neovasculatureKDR
VEGF-R2
Prostate/tumor vasculaturePSMA

Quick Inquiry

   Please input "biogene" as verification code.